Overview:

The ACA test helps diagnose scleroderma, particularly the limited form which affects the skin, blood vessels, and internal organs. The presence of these antibodies can suggest an autoimmune response where the immune system mistakenly attacks the body's own cells, leading to tissue damage.

Risk Assessment:

A positive ACA test can indicate a higher risk for:

• Scleroderma (limited form)
• CREST syndrome (a subtype of scleroderma)
• Raynaud's phenomenon (reduced blood flow to extremities)
• Esophageal dysmotility (difficulty swallowing)
• Pulmonary hypertension (high blood pressure in the lungs)

It is important to note that not everyone with a positive ACA test will develop these conditions, and false positives can also occur in healthy individuals or those with other autoimmune diseases.

Normal Range:

• Negative: No detectable ACA antibodies.
• Positive: ACA antibodies detected. The level of positivity can vary, but typically higher levels suggest more severe disease activity.

Interpretation:

• Positive result: The presence of ACA indicates the possibility of autoimmune disorders like scleroderma, particularly the limited cutaneous form. It may be more strongly linked with CREST syndrome (Calcinosis, Raynaud's phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia).
• Negative result: No ACA detected. This does not rule out scleroderma or other autoimmune conditions completely, but it suggests that ACA is unlikely to be the cause.

Sample Type:

The test is performed using a blood sample, typically obtained via a venipuncture (drawing blood from a vein). This sample is then analyzed for the presence of anti-centromere antibodies.